Biograil ApS: Financial statements 2022
CVR: 40666699
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Biograil ApS (CVR 40666699) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 26,317,577 and a net result of DKK 12,876,552 compared with DKK -7,932,078 the year before. Equity in the 2022 report amounted to DKK 44,815,540. The solvency ratio was 47%. The company had 6 employees in the financial year.
- Gross Profit
- DKK 26,317,577
- Profit/Loss
- DKK 12,876,552
- Equity
- DKK 44,815,540
- Total Assets
- DKK 95,347,334
- Employees
- 6
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 26.3 mio. | 12.9 mio. | 44.8 mio. | 6 |
| 2021 | - | -5.4 mio. | -7.9 mio. | 31.9 mio. | 3 |
Official annual report
Keep an eye on Biograil ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Biograil ApS has published its annual report for 2021. Gross profit came to DKK -5,373,412, and the net result was DKK -7,932,078.
About Biograil ApS
Biograil ApS is a Danish company of the type Anpartsselskab based in Roskilde, founded in 2019. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Karsten Lindhardt. The board consists of John Michael Barberich (chair), Karsten Lindhardt, Lars Hellerung Christiansen and Robert Samuel. The company's owners include Lindhardt Holdings ApS, MTI Biograil Invest A/S and Eli Lilly and Company. The company has 23 employees (2026). In 2025, the company reported a gross profit of DKK -13,192,351 and a net result of DKK -22,366,605 compared with DKK -17,084,308 the year before. Equity in the 2025 report amounted to DKK 102,217,548.